Download - 15. Pharmacotherapy GI Disorders
![Page 1: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/1.jpg)
Clinical Use of Drugs :Pharmacotherapy GI Disorders
![Page 2: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/2.jpg)
Upper GI Disorders
GI Anatomic region
![Page 3: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/3.jpg)
Gastric Acid Secretion⇨ Neuronal
– sight, smell, taste → cholinergic pathway⇨ Physical
– strecth → ↑acetylcholine & ↑gastrin⇨ Hormonal
● Stimulate parietal cells to secrete gas-tric acid
⇨ Gastrin⇨ Acetylcholine⇨ Histamine
Proton pump (H+/K+- ATPase)
Acid Secretion
![Page 4: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/4.jpg)
Physiological & Pharmacological Gastric Acid Secretion
![Page 5: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/5.jpg)
Pharmacotherapy of Acid – Related Disorders
Acid-suppressing drugsProton-pump Inhibitors (PPIs)Proton-pump Inhibitors (PPIs)⇨ Five PPIs available in clinical use : Omeprazole,
Esomeprazole, Lansoprazole, Rabeprazole, & Pantoprazole
– Similar in their pharmacological properties⇨ All PPIs have equivalent efficacy at comparable
doses⇨ PPIs diminish daily production of acid by 80 –
95% → most potent gastric suppressorsmost potent gastric suppressors
![Page 6: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/6.jpg)
⇨ PPIs → prodrugsprodrugs, require activation in acid envi-ronment → tetracyclic sulfenamide → unable to diffuse back to canalicular membrane
⇨ Activated form of PPIs covalently bound to H+/K+-ATPase → Acid secretion resume after newly formed H+/K+-ATPase molecules → Pro-long acid suppression (24 – 48 hours)
⇨ PPIs block final steps of acid secretionPPIs block final steps of acid secretion ⇨ Effective in acid suppression regardless of other stimulat-
ing factors⇨ Dosage form : Enteric – coated drugs, enteric – coated gran-
ules, enteric – coated tablets, powdered in combination with bicarbonate → to prevent degradation by acid in the stomach
![Page 7: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/7.jpg)
Pharmacokinetics :⇨ Rapidly absorbed, highly protein – bound, ex-
tensively metabolized by hepatic CYPs● CYP2C19 & CYP3A4
– CYP2C19 genotype● Asian vs Caucasian or African American (23% vs (23% vs
3%)3%)⇨ Chronic renal failure does not lead to accumula-
tion of PPIs with once-a-day dosing⇨ Hepatic impairment substantially reduce
clearence of esomeprazole and lansoprazole
![Page 8: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/8.jpg)
⇨ Most common : nausea, abdominal pain, flatu-lence, & diarrhea
● Subacute myopathy, arthralgia, headache, & rash
⇨ Inhibition of CYP2C19, slower the clearence of phenytoin, disulfiram, & other drugs metabolized the same enzymes)
⇨ Increase expression of CYP1A2 (increase clearence of imipramine, antipsychotic drugs, tacrin, & theophylline)
⇨ Loss of gastric acidity → affect bioavailability of ketoconazole, ampicillin esters, & iron salts
⇨ Chronic use ≈ hip fracture, possibly decreasing Ca2+ absorption
Adverse Effects & Drug Interactions
![Page 9: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/9.jpg)
⇨ Most common : nausea, abdominal pain, flatu-lence, & diarrhea
● Subacute myopathy, arthralgia, headache, & rash
⇨ Inhibition of CYP2C19, slower the clearence of phenytoin, disulfiram, & other drugs metabolized the same enzymes)
⇨ Increase expression of CYP1A2 (increase clearence of imipramine, antipsychotic drugs, tacrin, & theophylline)
⇨ Loss of gastric acidity → affect bioavailability of ketoconazole, ampicillin esters, & iron salts
⇨ Chronic use ≈ hip fracture, possibly decreasing Ca2+ absorption
Adverse Effects & Drug Interactions
![Page 10: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/10.jpg)
Therapeutic Use⇨ Promote healing of gastric & duodenal ul-
cers⇨ Gastroesophageal reflux disease (GERD)⇨ Hypersecretory conditions : Zolinger-Elli-
son syndrome⇨ Prevention of recurrence of NSAID – asso-
ciated gastric ulcers
![Page 11: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/11.jpg)
H2 Receptor Antagonists
⇨ H2RAs → competitive inhibitors of H2 recep-tor on basolateral membrane of parietal cells
⇨ Available drugs : Cimetidine, Ranitidine, Famotidine, Nizatidine
● Differ in pharmacokinetics & propensity to cause drug interations
⇨ H2RAs predominantly inhibit basal acid secre-tion → suppressing nocturnal acid secretion
⇨
![Page 12: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/12.jpg)
Pharmacokinetics
⇨ Rapidly absorbed, peak serum concentration achieved within 1 – 3 hours
⇨ Small percentage of H2RAs are protein-bound⇨ Liver disease per se is not indication for dose
adjustment⇨ Excreted by kidneys through filtration & tubular
secretion → reduce dose on patients with re-duced creatinine clearence
![Page 13: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/13.jpg)
Adverse Effects & Interactions⇨ H2RAs generally well-tolerated
⇨ Low incidence of AEs : diarrhea, headache, fatigue, muscular pain, & constipation
⇨ Neurologic : headache, dizziness, drowsiness, lethargy, hallu-cination, psychosis)
⇨ Long-term use :– Cimetidine at high doses → inhibit testosterone binding to
androgen receptors & inhibition of CYP reduce hydroxyla-tion of estradiol
– Galactorrhea in women, and gynecomastia, reduced Galactorrhea in women, and gynecomastia, reduced sperm counts & impotence in mensperm counts & impotence in men
⇨ Blood dyscrasia including thrombocytopenia have been reported
⇨ H2RAs cross the placenta & excreted in breast milk
![Page 14: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/14.jpg)
Therapeutic Uses⇨ Promote healing of gastric & duodenal ulcers⇨ Treat uncomplicated GERD⇨ Prevent occurrence of stress ulcers
![Page 15: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/15.jpg)
Agents that Enhance Mucosal Defences
Prostaglandin Analog : Misoprostol⇨ Synthetic analog of PGE1⇨ Gastric acid secretion inhibition – Dose related
⇨ 100 – 200 ug significantly inhibit basal secretion ( up to 95%) or food – stimulated secretion ( 85% inhibition)
⇨ Cytoprotective role of prostaglandin toward gastric acidity⇨ Stimulate Gi pathway → decreasing cAMP & gastric acid se-
cretion⇨ Stimulate mucin & bicarbonate secretion⇨ Increase blood flow
⇨ Recommended dose for ulcer prophylaxis : 200 ug four times a day
● Frequent dosing limited its use → inconvenience⇨
![Page 16: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/16.jpg)
⇨ Misoprostol can cause exacerbation of inflamma-tory bowel disease
⇨ Contraindicated in pregnancy → increase uterine contractility
Therapeutic Use⇨ To prevent NSAID-induced mucosal injury
![Page 17: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/17.jpg)
Sucralfate⇨ Sulfated polysaccaride → Octasulfate of sucrose
⇨ Inhibit pepsin-mediated hydrolisis of mucosal proteins con-tributes to mucosal erosion & ulceration
⇨In acid environment (pH<4), sucralfate → cross-linking → viscous & sticky polymer that adhere to epithelial cells & ul-cer crater up to 6 hours after single dose
⇨Stimulating secretion of PGs & growth factors
Therapeutic Use⇨ In critically patients, sucralfate may offer advantage
over PPIs & H2RAs in preventing stress ulcers⇨ Condition associated with mucosal inflammation / ul-
ceration which is not responsive to acid suppression such as oral mucositis (radiation & aphtous ulcer), bile reflux gastropathy
![Page 18: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/18.jpg)
Bismuth Salts⇨ Binding to and protecting mucosal lesion⇨ Enhancing cellular protective mechanims⇨ Antimicrobial effects, primarily againts H.py-
lori⇨ Frequently use in combination with other an-
tibiotics to eradicate H.pylori
Prokinetic agentsProkinetic agentsMetoclopramide & Betanechol⇨ Stimulate motility of upper GI & increase LES
(lower esophageal sphincter)⇨ Patients with delayed gastric emptying or refractory to
other available treatment options
![Page 19: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/19.jpg)
General Guidelines of medical management of Gastroesophageal Reflux Disease (GERD)
![Page 20: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/20.jpg)
![Page 21: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/21.jpg)
Meta-analysis of H2-receptor antagonists Meta-analysis of H2-receptor antagonists on Functional (Non-Ulcer) Dyspepsiaon Functional (Non-Ulcer) Dyspepsia
![Page 22: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/22.jpg)
Meta-analysis of H2-receptor antagonists Meta-analysis of H2-receptor antagonists on Functional (Non-Ulcer) Dyspepsiaon Functional (Non-Ulcer) Dyspepsia
![Page 23: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/23.jpg)
Comparison of Prokinetic, Acid Suppression, and Comparison of Prokinetic, Acid Suppression, and Antianxiety Therapies in Functional DyspepsiaAntianxiety Therapies in Functional Dyspepsia
Both Mosapride and Famotidine significantly improved the symptoms of Functional Dyspepsia within 2 weeks and the improvement was maintained for 8 weeks after the beginning of the study (p < 0.001)
![Page 24: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/24.jpg)
![Page 25: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/25.jpg)
Meta-analysis : Helicobacter pylori eradication improve symptoms in non-ulcer dyspepsia ?
![Page 26: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/26.jpg)
![Page 27: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/27.jpg)
PPIs vs AH2 : Effect on persistent or rebleeding of peptic ulcer
![Page 28: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/28.jpg)
![Page 29: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/29.jpg)
In patients with peptic ulcer and H. pylori infection, prolonging In patients with peptic ulcer and H. pylori infection, prolonging therapy with proton pump inhibitor after a triple therapy for 7 therapy with proton pump inhibitor after a triple therapy for 7 days with a proton pump inhibitor and two antibiotics is not days with a proton pump inhibitor and two antibiotics is not necessary to induce ulcer healingnecessary to induce ulcer healing
![Page 30: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/30.jpg)
Step-Up vs Step-Down Therapy in New-Onset Dyspepsia
⇨ Double-blind, randomized controlled trial● Step-up therapy : started with antacids, switched to
H2-receptor antagonists, and then ended with proton pump inhibitors (PPIs)
● Step-Down therapy : reversed order
– Step-Up therapy somewhat more Step-Up therapy somewhat more cost effectivecost effective than a than a step-down approach, but effectiveness of treatment step-down approach, but effectiveness of treatment and adverse events are similar.and adverse events are similar.
![Page 31: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/31.jpg)
![Page 32: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/32.jpg)
Nausea & VomitingPatophysiology of Emesis⇨ Nausea, the imminent need to vomit
● Associated with gastric stasis⇨ Retching,
⇨ Labored movement of thoracic & abdominal muscles before vomiting
⇨ Vomit● Forceful of GI contents caused by GI retroperistalsis
⇨ Act of vomiting require coordinated contraction of abdominal muscles, pylorus, antrum, raised gastric cardia, diminished lower esophageal sphincter, & esophageal dilatation
⇨ Chemoreceptor trigger zone (CTZ)⇨ Neurotransmitter receptor : cholinergic, histaminic, serotoner-
gic, dopaminergic, opiate, neurokinin, & benzodiazepin recep-tors
![Page 33: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/33.jpg)
Specific etiologies of Nausea & Vomiting
![Page 34: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/34.jpg)
Emetogenicity of Chemoterapeutic Agents
![Page 35: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/35.jpg)
Emetogenicity of Chemoterapeutic Agents
![Page 36: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/36.jpg)
Presentation of Nausea & Vomiting
![Page 37: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/37.jpg)
![Page 38: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/38.jpg)
TreatmentNon pharmacologic⇨ Dietary restriction if appropiate⇨ Stable physical position⇨ Psychological & behavioral intervention
● Relaxation● Bio-feedback● Self-hypnosis● Cognitive distraction● Guided imagery● Systematic desentization
⇨ Etc
Pharmacological intervention
![Page 39: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/39.jpg)
Pharmacological Intervention
Factors that enable clinician to discriminate the choices of antiemetic must be recognized, :⇨ The suspected etiology of symptoms⇨ Frequency, duration, & severity of the episodes⇨ The ability of patients to use oral, rectal, in-
jectable or transdermal medication⇨ The success of previous antiemetic medication
![Page 40: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/40.jpg)
![Page 41: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/41.jpg)
Mechanism of Action and Indications
⇨ Anticholinergic agents (ACh blockers)⇨ Bind to and block acetylcholine (ACh) receptors in the inner ear
labyrinth⇨ Block transmission of nauseating stimuli to CTZ ⇨ Also block transmission of nauseating stimuli from the reticular for-
mation to the VC⇨ Scopolamine ⇨ Also used for motion sickness
![Page 42: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/42.jpg)
Mechanism of Action⇨ Antihistamine agents (H1 receptor blockers)
⇨ Inhibit ACh by binding to H1 receptors
⇨ Prevent cholinergic stimulation in vestibular and retic-ular areas, thus preventing N&V
⇨ Diphenhydramine (Benadryl), meclizine (Antivert), promethazine (Phenergan)
⇨ Also used for nonproductive cough, allergy symptoms, sedation
![Page 43: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/43.jpg)
Mechanism of Action (cont'd)
⇨ Neuroleptic agents⇨ Block dopamine receptors on the CTZ⇨ chlorpromazine (Thorazine), prochlorperazine (Com-
pazine)⇨ Also used for psychotic disorders, intractable hiccups
![Page 44: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/44.jpg)
Mechanism of Action (cont'd)⇨ Prokinetic agents
⇨ Block dopamine in the CTZ⇨ Cause CTZ to be desensitized to impulses it receives
from the GI tract⇨ Also stimulate peristalsis in GI tract, enhancing empty-
ing of stomach contents⇨ Metoclopramide (Reglan)⇨ Also used for GERD, delayed gastric emptying
![Page 45: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/45.jpg)
Mechanism of Action (cont'd)
⇨ Serotonin blockers⇨ Block serotonin receptors in the GI tract, CTZ, and VC⇨ Dolasetron (Anzemet), granisetron (Kytril), on-
dansetron (Zofran)⇨ Used for N&V for patients receiving chemotherapy
and postoperative nausea and vomiting
![Page 46: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/46.jpg)
Mechanism of Action (cont'd)
⇨ Tetrahydrocannabinoids (THC)⇨ Major psychoactive substance in marijuana⇨ Inhibitory effects on reticular formation, thalamus,
cerebral cortex⇨ Alter mood and body’s perception of its surroundings
![Page 47: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/47.jpg)
Mechanism of Action (cont'd)
⇨ Tetrahydrocannabinoids (cont'd)⇨ dronabinol (Marinol)⇨ Used for N &V associated with chemotherapy, and
anorexia associated with weight loss in AIDS patients
![Page 48: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/48.jpg)
Side Effects
⇨ Vary according to agent used⇨ Stem from their nonselective blockade of various
receptors
![Page 49: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/49.jpg)
Management Implications
⇨ Assess complete nausea and vomiting history, in-cluding precipitating factors
⇨ Assess current medications⇨ Assess for contraindications and potential drug
interactions
![Page 50: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/50.jpg)
![Page 51: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/51.jpg)
![Page 52: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/52.jpg)
![Page 53: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/53.jpg)
Laxative, Cathartics, & Therapy of Constipation
⇨ Fluid content is principal determinant of stool con-tent (70 – 85% contain water)
⇨ 8 – 9 L of fluid enter small intestine ⇒ 1 – 1.5 L crossing ileocaecal valve, colon extracts most of remaining fluid ⇒ ∽ 100 ml of fecal water daily
⇨ Secretory changes, bowel movement, transit time, extent of absorption determine the consistency of stool⇨ Neurohormonal mechanisms, pathogens, drugs might alter
processes above⇨ Up to 60% of patients with constipation have normal
colonic transit⇨ Predominant factors underlying constipation often not ob-
vious ⇒ therapy remain empiric & non specific
![Page 54: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/54.jpg)
⇨ Laxation : evacuation of formed fecal material from rectum)
⇨ Catharsis : evacuation of unformed, usually wa-tery fecal material from the entire colon
– The terms frequently used interchangebly⇨ Mode of Action of Laxative :
– Enhancing retention of intraluminal fluid by hy-drophilic or osmotic mechanims
– Decreasing the net absorption of fluid by effects on small- and large-bowel fluid & electrolyte transport
– Altering motility by either inhibiting segmenting (nonpropulsive) contractions or stimulating propul-sive contractions
![Page 55: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/55.jpg)
![Page 56: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/56.jpg)
![Page 57: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/57.jpg)
![Page 58: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/58.jpg)
Diarrhea
⇨ Abnormal frequent passage of loose stool or⇨ Abnormal passage of stools with increased frefre--
quency, fluidityquency, fluidity, and weightweight, or with increased increased stool water excretionstool water excretion
![Page 59: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/59.jpg)
Antidiarrheal agents⇨ Oral rehydration solution is the CORNERSTONE CORNERSTONE
OF THERAPYOF THERAPY for patient with acute illness re-sulting significant diarrhea
⇨ Pharmacotherapy should be reservedshould be reserved for patients with persistence symptoms
⇨
![Page 60: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/60.jpg)
Diarrhea (cont'd)
Acute diarrhea⇨ Sudden onset in a previously healthy person⇨ Lasts from 3 days to 2 weeks⇨ Self-limiting⇨ Resolves without sequelae
![Page 61: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/61.jpg)
Diarrhea (cont'd)
Chronic diarrhea⇨ Lasts for more than 3 weeks⇨ Associated with recurring passage of diarrheal
stools, fever, loss of appetite, nausea, vomiting, weight loss, and chronic weakness
![Page 62: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/62.jpg)
Causes of Diarrhea
Acute Diarrhea
Bacterial
Viral
Drug induced
Nutritional
Protozoal
Chronic Diarrhea
Tumors
Diabetes
Addison’s disease
Hyperthyroidism
Irritable bowel syndrome
Etc.
![Page 63: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/63.jpg)
Antidiarrheals: Mechanism of Action
Adsorbents⇨ Coat the walls of the GI tract⇨ Bind to the causative bacteria or toxin, which is
then eliminated through the stool⇨ Examples: bismuth subsalicylate (Pepto-Bismol),
kaolin-pectin, activated charcoal, attapulgite (Kaopectate)
![Page 64: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/64.jpg)
Antidiarrheals: Mechanism of Action (cont'd)
Anticholinergics⇨ Decrease intestinal muscle tone and peristalsis of
GI tract⇨ Result: slowing the movement of fecal matter
through the GI tract⇨ Examples: belladonna alkaloids (Donnatal), at-
ropine
![Page 65: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/65.jpg)
Antidiarrheals: Mechanism of Action (cont'd)
Intestinal flora modifiers⇨ Bacterial cultures of Lactobacillus organisms work by:
⇨ Supplying missing bacteria to the GI tract⇨ Suppressing the growth of diarrhea-causing bacteria
⇨ Example: L. acidophilus (Lactinex)
![Page 66: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/66.jpg)
Antidiarrheals: Mechanism of Action (cont'd)
Opiates⇨ Decrease bowel motility and relieve rectal
spasms⇨ Decrease transit time through the bowel, allow-
ing more time for water and electrolytes to be ab-sorbed
⇨ Examples: paregoric, opium tincture, codeine, loperamide (Imodium), diphenoxylate (Lomotil)
![Page 67: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/67.jpg)
Antidiarrheal Agents: Side Effects
Adsorbents⇨ Increased bleeding time⇨ Constipation, dark stools⇨ Confusion, twitching⇨ Hearing loss, tinnitus, metallic taste, blue gums
![Page 68: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/68.jpg)
Antidiarrheal Agents: Side Effects (cont'd)
Anticholinergics⇨ Urinary retention, hesitancy, impotence⇨ Headache, dizziness, confusion, anxiety, drowsiness⇨ Dry skin, rash, flushing⇨ Blurred vision, photophobia, increased intraocular pressure⇨ Hypotension, hypertension, bradycardia, tachycardia
![Page 69: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/69.jpg)
Antidiarrheal Agents: Side Effects (cont'd)
Opiates⇨ Drowsiness, sedation, dizziness, lethargy⇨ Nausea, vomiting, anorexia, constipation⇨ Respiratory depression⇨ Bradycardia, palpitations, hypotension⇨ Urinary retention⇨ Flushing, rash, urticaria
![Page 70: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/70.jpg)
Antidiarrheal Agents: Interac-tions
⇨ Adsorbents decrease the absorption of many agents, including digoxin, clindamycin, quini-dine, and hypoglycemic agents
⇨ Adsorbents cause increased bleeding time when given with anticoagulants
⇨ Antacids can decrease effects of anticholinergic antidiarrheal agents
![Page 71: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/71.jpg)
Antidiarrheal Agents: Implications
⇨ Obtain thorough history of bowel patterns, gen-eral state of health, and recent history of illness or dietary changes, and assess for allergies
⇨ DO NOT give bismuth subsalicylate to children younger than age 16 or teenagers with chicken-pox because of the risk of Reye’s syndrome
![Page 72: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/72.jpg)
Antidiarrheal Agents:Implications
⇨ Use adsorbents carefully in geriatric patients or those with decreased bleeding time, clotting disorders, recent bowel surgery, confusion
⇨ Anticholinergics should not be administered to patients with a history of glaucoma, BPH, urinary retention, recent bladder surgery, cardiac problems, myasthenia gravis
![Page 73: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/73.jpg)
Antidiarrheal Agents: Implications
⇨ Teach patients to take medications exactly as prescribed and to be aware of their fluid intake and dietary changes
⇨ Assess fluid volume status, I&O, and mucous membranes before, during, and after initiation of treatment
⇨ Teach patients to notify their physician immedi-ately if symptoms persist
⇨ Monitor for therapeutic effect
![Page 74: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/74.jpg)
![Page 75: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/75.jpg)
![Page 76: 15. Pharmacotherapy GI Disorders](https://reader035.vdocuments.us/reader035/viewer/2022062307/552b7db1550346d0478b471f/html5/thumbnails/76.jpg)
Selected Antidiarrheal AgentsSelected Antidiarrheal Agents